LFCRHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Lifecore Biomedical, Inc. hold a median 12-month price target of $6.28 — -2.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 6 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Lifecore Biomedical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (65): Smaller than most of the companies we track.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −2.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Barrington Research | Downgrade | Market Perform | — |
| 28 Sept 2026 | William Blair | Downgrade | Market Perform | — |
| 16 June 2026 | Barrington Research | Maintains | Outperform | — |
| 16 June 2026 | Barrington Research | Maintains | Outperform | $6.00 → $6.50 |
| 29 Apr 2026 | Barrington Research | Maintains | Outperform | — |
| 27 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 24 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 17 Mar 2026 | Barrington Research | Upgrade | Outperform | — |
| 4 Sept 2025 | Keybanc | Initiates | Sector Weight | — |
| 21 May 2025 | William Blair | Initiates | Outperform | — |
| 3 Jan 2025 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 22 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 5 Sept 2024 | Craig-Hallum | Initiates | Buy | — |
| 28 Aug 2024 | Barrington Research | Downgrade | Market Perform | — |
| 1 Sept 2023 | Barrington Research | Maintains | Outperform | — |
| 1 Sept 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
| 2 June 2023 | Barrington Research | Maintains | Outperform | — |
| 24 May 2023 | Barrington Research | Maintains | Outperform | — |
| 21 Mar 2023 | Barrington Research | Maintains | Outperform | — |
| 20 Mar 2023 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Lifecore Biomedical, Inc. returned −4.5% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 13% of US stocks
Cheaper than 53% of US stocks
Cheaper than 97% of US stocks
Cheaper than 5% of US stocks
Higher than 85% of US stocks
Higher than 33% of US stocks
Higher than 43% of US stocks
Higher than 60% of US stocks
Higher than 15% of US stocks
Higher than 99% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lifecore Biomedical, Inc. has a market value of $244.1M and an enterprise value of $433.5M.
Revenue in the twelve months to 30 June 2026: $124.9M. The latest quarter grew 47.3% year on year.
Net income over the same four quarters: −$32.3M, a −25.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.97.
Free cash flow in the twelve months to 30 June 2026: $4.2M.
Trailing P/E: 56.2×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lifecore Biomedical, Inc. employs 382 people — $327K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lifecore Biomedical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lifecore Biomedical announced it will participate in three upcoming industry events. The excerpt does not identify the events.
Why it matters — LFCR watchers may note the company’s upcoming industry-event participation, though the excerpt provides no further details.
Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations it is conducting into several companies, including Lifecore Biomedical, Inc. (Nasdaq – LFCR). The firm invites shareholders to discuss the matter at no cost or financial obligation.
Why it matters — LFCR watchers would care because the firm's announcement indicates an active shareholder investigation into the company, which could draw attention to governance or disclosure concerns.
Halper Sadeh LLC has announced it is investigating whether Lifecore Biomedical, Inc. (LFCR) and another company, SSTI, are obtaining fair deals for their shareholders. The investigation raises concerns that insiders may receive substantial financial benefits not available to ordinary shareholders.
Why it matters — A law firm investigation into whether shareholders are receiving fair treatment in a deal could be relevant to LFCR investors monitoring the transaction's terms.
Law firm Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti Jr., is investigating the proposed sale of Lifecore Biomedical, Inc. to Webster Equity Partners, under which shareholders would receive $6.28 in cash per share. The firm is examining whether this consideration and the sale process were adequate.
Why it matters — LFCR watchers would care because the investigation could signal concerns about the fairness of the transaction price and process for shareholders in the proposed sale.
Brodsky & Smith issued a shareholder update reminding investors of an investigation into Lifecore Biomedical, Inc. and other companies. The firm invites LFCR shareholders to contact them at no cost to discuss the investigation.
Why it matters — A law firm announcing an investigation into Lifecore Biomedical signals potential legal or governance concerns that LFCR shareholders may want to monitor.
The 4 Wall Street analysts covering Lifecore Biomedical, Inc. have a median 12-month price target of $6.28, with estimates ranging from $6.28 to $6.28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Lifecore Biomedical, Inc., 0 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifecore Biomedical, Inc. 2 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Lifecore Biomedical, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (65 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies -2.5% from the last close, and Ticker Nerd's factor model ranks Lifecore Biomedical, Inc. 2 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lifecore Biomedical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.28 to $6.28 over the next 12 months.
Lifecore Biomedical, Inc. returned -4.5% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products.
The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Lifecore Biomedical to Participate at Upcoming Industry Conferences". Lifecore Biomedical announced it will participate in three upcoming industry events. The excerpt does not identify the events.
Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products. The company provides development, aseptic fill-finish, and commercial manufacturing services for products packaged in syringes, vials, and cartridges. It also produces pharmaceutical-grade hyaluronic acid, a biomaterial used in a range of medical applications, including ophthalmic and orthopedic products. Lifecore Biomedical Inc. serves pharmaceutical and medical device customers that need regulated manufacturing expertise, formulation support, and process scale-up capabilities. Headquartered in Chaska, Minnesota, the company operates in the biopharmaceutical manufacturing and biomaterials markets, where it plays a specialized role in supporting complex injectable therapies and related healthcare products.
CEO Mr. Paul Josephs · 382 employees · United States · https://www.lifecore.com
